How to manage Deep Vein Thrombosis (DVT) in a patient already on Eliquis (apixaban)?

Management of DVT in a Patient Already on Eliquis (Apixaban)

If a patient develops DVT while already taking apixaban at therapeutic doses and is believed to be compliant, switch to low molecular weight heparin (LMWH) at least temporarily. 1

Initial Assessment

When a patient on apixaban develops DVT, this represents breakthrough thrombosis on anticoagulation, which is unusual and requires immediate evaluation:

• Confirm the diagnosis with objective imaging to ensure this is truly a new or recurrent DVT 1
• Verify medication compliance through careful history, pharmacy records, and patient interview 1
• Evaluate for underlying malignancy as occult cancer is a common cause of anticoagulation failure 1
• Review the current apixaban dosing to ensure the patient is on the correct therapeutic dose (10 mg twice daily for first 7 days, then 5 mg twice daily for DVT treatment) 2, 3

Recommended Management Strategy

Switch to LMWH

The CHEST guidelines specifically recommend switching to LMWH for at least 1 month when patients experience recurrent VTE on therapeutic DOAC therapy 1. This applies to patients on apixaban, dabigatran, rivaroxaban, or edoxaban who are believed to be compliant 1.

LMWH Dosing

• Standard dosing: Enoxaparin 1 mg/kg subcutaneously twice daily or 1.5 mg/kg once daily 2
• In cancer patients: Dalteparin 200 units/kg subcutaneously once daily for 1 month, then 150 IU/kg once daily for months 2-6 2

Duration of LMWH

Continue LMWH for at least 1 month before considering transition back to oral anticoagulation 1. If the patient remains on LMWH long-term and experiences another recurrent VTE, increase the LMWH dose by approximately one-quarter to one-third 1.

Special Considerations

If Cancer is Discovered

If malignancy is identified during workup, LMWH or oral factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) are preferred over warfarin 4, 5. For cancer-associated VTE, apixaban has demonstrated noninferiority to dalteparin without increased major bleeding risk 6, and both apixaban and edoxaban receive Category 1 recommendations from NCCN 4.

If Patient Was on Subtherapeutic Dosing

If the patient was taking apixaban 2.5 mg twice daily (the reduced dose for secondary prevention after 6 months) rather than the therapeutic 5 mg twice daily dose:

• Increase to therapeutic dosing: 10 mg twice daily for 7 days, then 5 mg twice daily 2, 3
• Do not switch to LMWH unless breakthrough occurs on confirmed therapeutic dosing 1

If Compliance is Questionable

• Address barriers to adherence including cost, dosing complexity, and patient understanding 2
• Consider LMWH as it can be administered by visiting nurses or family members if self-administration is unreliable 1
• Supervised anticoagulation may be necessary in some cases 1

Common Pitfalls to Avoid

• Do not simply increase the apixaban dose beyond FDA-approved dosing, as there is no evidence supporting this approach and it increases bleeding risk 3
• Do not assume non-compliance without investigation - true anticoagulation failure can occur and requires alternative therapy 1
• Do not overlook cancer screening - breakthrough thrombosis is a red flag for occult malignancy 1
• Do not use bridging therapy when switching from apixaban to LMWH, as apixaban can be stopped and LMWH started immediately 3

Long-Term Management

After the acute phase on LMWH, decisions about extended anticoagulation should consider:

• Indefinite anticoagulation is recommended for unprovoked VTE or VTE with persistent risk factors 5
• If returning to oral therapy, consider whether the initial failure was due to compliance issues, drug interactions, or true therapeutic failure 1
• If cancer-associated, continue anticoagulation indefinitely unless bleeding risk is prohibitive 4, 5